Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants

PURPOSE: Inhaled drug delivery is an attractive route by which to deliver drugs to lungs of patients with idiopathic pulmonary fibrosis (IPF). GSK3008348 is a potent and selective small molecule being developed as the first inhaled inhibitor of the αvβ6 integrin for the treatment of IPF. The phase 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Maden, Charlotte H., Fairman, David, Chalker, Michelle, Costa, Maria J., Fahy, William A., Garman, Nadia, Lukey, Pauline T., Mant, Tim, Parry, Simon, Simpson, Juliet K., Slack, Robert J., Kendrick, Stuart, Marshall, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942357/
https://www.ncbi.nlm.nih.gov/pubmed/29532104
http://dx.doi.org/10.1007/s00228-018-2435-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5942357/
https://www.ncbi.nlm.nih.gov/pubmed/29532104
http://dx.doi.org/10.1007/s00228-018-2435-3

Ejemplares similares